EvsyukovaI, SomarelliJA, GregorySG, et al.Alternative splicing in multiple sclerosis and other autoimmune diseases. RNA Biol, 2010; 7(4):462–473.
2.
FengX, BaoR, LiL, et al.Interferon-beta corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection. EBioMedicine, 2019; 49:269–283.
3.
GraberJJ, McGrawCA, KimbroughD, et al.Overlapping and distinct mechanisms of action of multiple sclerosis therapies. Clin Neurol Neurosurg, 2010; 112(7):583–591.
4.
HeckerM, RugeA, PutscherE, et al.Aberrant expression of alternative splicing variants in multiple sclerosis – A systematic review. Autoimmun Rev, 2019; 18(7):721–732.
5.
NagasawaCK, Garcia-BlancoMA. Early splicing complexes and human disease. Int J Mol Sci, 2023; 24(14).
6.
NguyenK, OlcerM, Howlett-PrietoQ, et al.Prolonged interferon-stimulated ene and protein signatures in multiple sclerosis induced by PEGylated IFN-beta-1a compared to Non-PEGylated IFN-beta-1a. J Interferon Cytokine Res, 2023; 43(3):108–120.
7.
PutscherE, HeckerM, FitznerB, et al.Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing. Front Immunol, 2022; 13:931831.
8.
RederAT, GoelA, GarciaT, et al.Alternative splicing of RNA Is excessive in multiple sclerosis and not linked to gene expression levels: Dysregulation Is corrected by IFN-beta. J Interferon Cytokine Res, 2024.
9.
YadavSK, MindurJE, ItoK, et al.Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol, 2015; 28(3):206–219.
